Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the anti-tumor activity of SU011248 (sunitinib) in cytokine-refractory metastatic
renal cell carcinoma (RCC) when administered in a continuous treatment regimen